Leerink Partners Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $4
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $8
HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $8 Price Target
Amylyx Pharma Analyst Ratings
Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Amylyx Pharmaceuticals Inc (AMLX)
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $3
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Taysha Gene Therapies (TSHA) and Lexeo Therapeutics, Inc. (LXEO)
Bank of America Securities Keeps Their Hold Rating on Amylyx Pharmaceuticals Inc (AMLX)
Buy Rating Affirmed for Amylyx Pharmaceuticals Amid Promising Drug Trials and FDA Breakthrough Designation
Balancing Potential and Uncertainty: Hold Rating on Amylyx Pharmaceuticals Post-Avexitide Acquisition
Analyst Ratings For Amylyx Pharma
Goldman Sachs Adjusts Price Target on Amylyx Pharmaceuticals to $4 From $3, Maintains Neutral Rating
Goldman Sachs Maintains Neutral on Amylyx Pharma, Raises Price Target to $4
Amylyx Pharma Analyst Ratings
Amylyx Pharmaceuticals: Holding Steady Amidst Expansion and Market Skepticism
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Centene (CNC) and Radnet (RDNT)
Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Teladoc (TDOC) and Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $8 Price Target
Amylyx Pharmaceuticals Inc: Strong Buy Rating on Avexitide's Potential and Strategic Pipeline Expansion